Vascular endothelial growth factor expression in invasive papillary thyroid carcinoma

Thyroid

Volumn 19, Issue 11, 2009, Pages 1233-1237

  De Araujo Filho, Vergilius José Furtado ^a   Alves, Venancio Avancini Ferreira ^a   De Castro, Ines Vieira ^a   Lourenço, Silvia Vanessa ^a   Cernea, Claudio Roberto ^a   Brandão, Lenine Garcia ^a   Ferraz, Alberto R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; VASCULOTROPIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; THYROID PAPILLARY CARCINOMA;

ADULT; CARCINOMA, PAPILLARY; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STAINING AND LABELING; THYROID GLAND; THYROID NEOPLASMS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70449334553     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2008.0179     Document Type: Article

References (43)

1. Cotran R, Kumar V, Collins T 2000 Neoplasia. In: Robbins SL (ed) Patologia Estrutural e Funcional. Guanabara Koogan, Rio de Janeiro, pp 232-295.
2. Dray TG, Hardin NJ, Sofferman RA 1995 Angiogenesis as a prognostic marker in early head and neck cancer. Ann Otol Rhinol Laryngol 104:724-729.
3. Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S 2007 Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol 88:271-277.
4. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, Blair E, Francis GL, Tuttle RM 2001 Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129:552-558.
5. Fellmer PT, Sato K, Tanaka R, Okamoto T, Kato Y, Kobayashi M, Shibuya M, Obara T 1999 Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. Surgery 126:1056-1061.
6. Fenton C, Patel A, Dinauer C, Robie, DK, Tuttle RM, Francis GL 2000 The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 10:349-357. (Pubitemid 30256865)
7. Katoh R, Miyagi E, Kawaoi A, Hemmi A, Komiyama A, Oyama T, Shibuya M 1999 Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. Hum Pathol 30:891-897.
8. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE, Clark OH 1997 Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. Clin Endocrinol Metab 82:3741-3747.
9. Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S, Carcangiu ML 1999 Downregulation of p27KIP1 and Ki67=Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol 23:678-685.
10. Klein M, Picard E, Vignaud JM, Marie B, Bresler L, Toussaint B, Weryha G, Duprez A, Leclère J 1999 Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 161:41-49.
11. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plenat F, Leclère J, Duprez A, Weryha G 2001 Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 86:656-658.
12. Toda S, Nishimura T, Yamada S, Koike N, Yonemitsu N, Watanabe K, Matsumura S, Gartner R, Sugihara H 1999 Immunohistochemical expression of growth factors in subacute thyroiditis and their effects on thyroid folliculogenesis and angiogenesis in collagen gel matrix culture. J Pathol 188:415-422.
13. Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM, Shong M 2006 Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 91:3667-3670.
14. Rosai J, Carcangiu ML, Delellis RA 1992 Atlas of Tumor Pathology-Tumors of the Thyroid Gland, third series, fascicle
15. Armed Forces Institute of Pathology, Washington DC.
16. Akslen LA, Livolsi VA 2000 Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Hum Pathol 31:439-442.
17. Cernea CR 2001 Carcinomas cutaneos com acometimento suspeito ou comprovado da base do cranio: fatores cl?́nicos, histopatoló gicos e bioló gicos. Sao Paulo. 190 p. Tese (Livre- Docência)-Faculdade de Medicina, Universidade de São Paulo.
18. Rosner B 1986 Hypothesis testing: categorical data. In: Crockett C, Day A, Raburn K, Vezilich M, Purington L, Campobasso L (eds) Fundamentals of Biostatistics. PWS Publishers, Boston, pp 326-342.
19. Rosner B 1986 Multisample inference. In: Crockett C, Day A, Raburn K, Vezilich M, Purington L, Campobasso L (eds) Fundamentals of Biostatistics. PWS Publishers, Boston pp 442-480.
20. Soh EY, Eigelberger MS, Kim KJ, Wong MG, Young DM, Clark OH, Duh QY 2000 Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery 128:1059-1065.
21. Hoffmann S, Rockenstein A, Ramaswamy A, Celik I, Wunderlich A, Lingelbach S, Hofbauer LC, Zielke A 2007 Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. Mol Cell Endocrinol 264:74-81.
22. Hoffmann S, Glä ser S, Wunderlich A, Lingelbach S, Dietrich C, Burchert A, Mü ller H, Rothmund M, Zielke A 2006 Targeting the EGF=VEGF-R system by tyrosine-kinase inhibitors-a novel antiproliferative=antiangiogenic strategy in thyroid cancer. Langenbecks Arch Surg 391:589-596.
23. Hoffmann S, Wunderlich A, Celik I, Maschuw K, Hassan I, Hofbauer LC, Zielke A 2006 Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy. J Cell Biochem 98:954-965.
24. Poulaki V, Mitsiades CS, McMullan C, Sykoutri D, Fanourakis G, Kotoula V, Tseleni-Balafouta S, Koutras DA, Mitsiades N 2003 Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocrinol Metab 88:5392-5398.
25. Ramsden JD 2000 Angiogenesis in the thyroid gland. J Endocrinol 166:475-480.
26. Zachary I 1998 Vascular endothelial growth factor. Int J Biochem Cell Biol 30:1169-1174.
27. Lin JD, Chao TC 2005 Vascular endothelial growth factor in thyroid cancers. Cancer Biother Radiopharm 20:648-661.
28. Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, Pierotti MA, Bongarzone I 1999 Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 155:1967-1976.
29. Giatromanolaki A, Koukourakis MI, Sivridis E, Thorpe PE, Brekken RA, Konstantinos S, Fountzilas G, Gatter KC, Harris AL 2000 Tumor specific activation of the VEGF=KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas. Clin Exp Metastasis 18:313-319.
30. Guang-WU H, Sunagawa M, Jie-Em L, Shimada S, Gang Z, Tokeshi Y, Kosugi T 2000 The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. Laryngoscope 110:2066-2069.
31. Homer JJ, Anyanwu K, Ell SR, Greenman J, Stafford ND 1999 Serum vascular endothelial growth factor in patients with head and neck squamous cell carcinoma. Clin Otolaryngol 24:426-430.
32. Millikan KW, Mall JW, Myers JA, Hollinger EF, Doolas A, Saclarides TJ 2000 Do angiogenesis and growth factor expression predict prognosis of esophageal cancer? Am Surg 66:401-405.
33. Mineta H, Miura K, Ogino T, Takebayashi S, Misawa K, Ueda Y, Suzuki I, Dictor M, Borg A, Wennerberg J 2000 Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br J Cancer 83:775-781.
34. Traweek ST, Kandalaft PL, Mehta P, Battifora H 1991 The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. Am J Clin Pathol 96:25-31.
35. Gerard AC, Many MC, Daumerie C, Costagliola S, Miot F, Devijlder JJ, Colin IM, Denef JF 2002 Structural changes in the angiofollicular units between active and hypofunctioning follicles align with differences in the epithelial expression of newly discovered proteins involved in iodine transport and organification. J Clin Endocrinol Metab 87:1291-1299.
36. Nagura S, Katoh R, Miyagi E, Shibuya M, Kawaoi A 2001 Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. Hum Pathol 32:10-17.
37. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G 1995 Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11:1569-1579.
38. Siironen P, Ristimä ki A, Narko K, Nordling S, Louhimo J, Andersson S, Haapiainen R, Haglund C 2006 VEGF-C and COX-2 expression in papillary thyroid cancer. Endocr Relat Cancer 13:465-473.
39. Siironen P, Louhimo J, Nordling S, Ristimä ki A, Mäenpää H, Haapiainen R, Haglund C 2005 Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biol 26:57-64.
40. De La Torre NG, Buley I, Wass JA, Turner HE 2006 Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr Relat Cancer 13:931-944.
41. Yu XM, Lo CY, Chan WF, Lam KY, Leung P, Luk JM 2005 Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res 15:8063-8069.
42. Straight AM, Oakley K, Moores R, Bauer AJ, Patel A, Tuttle RM, Jimeno J, Francis GL 2006 Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemother Pharmacol 57:7-14.
43. Huang SM, Lee JC, Wu TJ, Chow NH 2001 Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg 25:302-306.